Management Strategies for Gastrointestinal Adverse Events with GLP-1RA Therapy There are various strategies that can be employed to help manage or mitigate potential gastrointestinal adverse events when initiating a GLP-1RA for the treatment of overweight or obesity
So theres definitely real-world evidence of a mortality benefit to these medications. And because the drugs can reduce the risk of serious health issues from untreated diabetes, they can improve lifespan in people with that condition, or prediabetes, as well
However, caution must be taken when examining exogenous gut peptide studies, as many times the dose is supraphysiological, and while there may be therapeutic relevance, it may not be an accurate representation of endogenous gut peptide action
Likewise, once a week administration of efpeglenatide, a long acting GLP-1RA, significantly reduced the body weight in obese patients (172)
Free radicals can react with normal cellular structures which in turn can cause damage and cell death